Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis
Selinexor Combined With Daratumumab and Dexamethasone (XDd) for the Treatment of Patients With Advanced Light-Chain Cardiac Amyloidosis: A Prospective, Multicenter, Phase II Clinical Study
The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis. The main questions it aims to answer are:
Does XDd regimen achieve hematologic complete response in patients with advanced light-chain cardiac amyloidosis? Does XDd regimen improve cardiac response, organ response, progression-free survival, overall survival, quality of life, and safety?
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Yini Wang
- 電話番号:+86-010-84005477
- メール:wangyini@ccmu.edu.cn
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥ 18 years.
Confirmed systemic light-chain amyloidosis, meeting both of the following:
- Tissue biopsy confirms amyloid deposition, and the amyloid precursor protein is immunoglobulin light chain or heavy-light chain. Pathologic evidence includes at least one of the following: Congo red staining positive with apple-green birefringence under polarized light microscopy; Light-chain restricted expression demonstrated by immunohistochemistry, immunofluorescence, or immunoelectron microscopy, or mass spectrometry confirming the precursor protein as immunoglobulin light chain; Electron microscopy showing nonbranching, rigid, randomly arranged fibrils with a diameter of 8 to 14 nm.
- Evidence of monoclonal immunoglobulin or free light chain in serum or urine, or detection of monoclonal plasma cells/B cells in bone marrow examination.
Clinical manifestations, physical examination, laboratory tests, or imaging studies confirm involvement of one or more organs, with mandatory cardiac involvement. Cardiac involvement is defined as either:
- Mean ventricular wall thickness > 12 mm on echocardiography, with other cardiac diseases excluded; or
- NT-proBNP > 332 ng/L in the absence of renal insufficiency and atrial fibrillation.
- Mayo 2004 stage IIIa or IIIb disease, including newly diagnosed and relapsed/refractory patients.
Measurable disease in light-chain amyloidosis, defined by at least one of the following:
- Serum monoclonal protein ≥ 0.5 g/dL by serum protein electrophoresis and immunofixation performed by the central laboratory;
- Serum free light chain ≥ 50 mg/L with an abnormal kappa/lambda ratio; or
- Difference between involved and uninvolved free light chains (dFLC) ≥ 50 mg/L. Note: Urine Bence Jones proteinuria alone is not sufficient to define measurable disease for eligibility.
- Not pregnant or breastfeeding. Men and women of childbearing potential must agree to use appropriate contraception before treatment, during treatment, during any treatment interruption, and for 4 weeks after treatment completion.
- Written informed consent has been signed by the participant. If the participant is unable to sign because of their medical condition, informed consent may be signed by a legal guardian or immediate family member.
Exclusion Criteria:
- Active hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, or other acquired or congenital immunodeficiency disorders.
- Baseline peripheral neuropathy or neuropathic pain of grade ≥ 2 according to NCI CTCAE v4.0.
- Major surgery within 30 days before enrollment.
- Epilepsy requiring medication, dementia, or other psychiatric conditions that prevent understanding of or compliance with the study protocol.
- Any severe physical or psychiatric illness that may interfere with participation in this clinical study.
- Any other condition that the investigator considers unsuitable for enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:XDd
|
Selinexor (X): 40 mg orally once weekly (QW) Daratumumab (D): 1800 mg per dose, subcutaneous injection; administered once weekly during cycles 1-2, once every 2 weeks during cycles 3-6, and once every 4 weeks from cycle 7 onward. One cycle is 4 weeks. Dexamethasone (d): 20-40 mg once weekly (QW) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Hematologic complete response rate
時間枠:From enrollment to the end of treatment at 1 year
|
From enrollment to the end of treatment at 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiac organ response rate
時間枠:From enrollment to the end of treatment at 1 year
|
From enrollment to the end of treatment at 1 year
|
|
|
Organ response rate (heart, kidney, and liver)
時間枠:From enrollment to the end of treatment at 1 year
|
From enrollment to the end of treatment at 1 year
|
|
|
Duration of response
時間枠:From first documented response until documented progression or death, assessed up to 1 years.
|
From first documented response until documented progression or death, assessed up to 1 years.
|
|
|
Time to response
時間枠:From first dose until first documented response, assessed up to 1 years
|
From first dose until first documented response, assessed up to 1 years
|
|
|
Progression-free survival
時間枠:From first dose until date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
|
From first dose until date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
|
|
|
Overall survival
時間枠:From first dose until date of death from any cause, assessed up to 12 months.
|
From first dose until date of death from any cause, assessed up to 12 months.
|
|
|
Quality of life assessed by EORTC QLQ-C30
時間枠:Through study completion, up to 1 year.
|
Mean change from baseline in EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global health status/Quality of life score (range 0-100; higher scores indicate better quality of life)
|
Through study completion, up to 1 year.
|
|
Incidence and Severity of Adverse Events
時間枠:From the first dose through 28 days after the last dose
|
From the first dose through 28 days after the last dose
|
|
|
Biomarker Outcome: dFLC
時間枠:Baseline and every 4 weeks during treatment, up to 12 months.
|
Change from baseline in difference between involved and uninvolved free light chains (dFLC) (mg/L).
|
Baseline and every 4 weeks during treatment, up to 12 months.
|
|
Biomarker outcome: NT-proBNP
時間枠:Baseline and every 4 weeks during treatment, up to 12 months.
|
Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) (pg/mL)
|
Baseline and every 4 weeks during treatment, up to 12 months.
|
|
Biomarker outcome: MRD
時間枠:Baseline and at end of treatment, up to 12 months.
|
Minimal residual disease (MRD) status in bone marrow (assessed by multiparameter flow cytometry of bone marrow).
|
Baseline and at end of treatment, up to 12 months.
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Huang XH, Liu ZH. The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China. Kidney Dis (Basel). 2016 Apr;2(1):1-9. doi: 10.1159/000444287. Epub 2016 Feb 25.
- Hou JH, Zhu HX, Zhou ML, Le WB, Zeng CH, Liang SS, Xu F, Liang DD, Shao SJ, Liu Y, Liu ZH. Changes in the Spectrum of Kidney Diseases: An Analysis of 40,759 Biopsy-Proven Cases from 2003 to 2014 in China. Kidney Dis (Basel). 2018 Feb;4(1):10-19. doi: 10.1159/000484717. Epub 2017 Dec 8.
- Morikawa K, Izumiya Y, Takashio S, Kawano Y, Oguni T, Kuyama N, Oike F, Yamamoto M, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Matsuzawa Y, Usuku H, Yamamoto E, Ueda M, Tsujita K. Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis. J Cardiol. 2025 Jun;85(6):440-446. doi: 10.1016/j.jjcc.2024.11.003. Epub 2024 Dec 4.
- Gregory Kaufman, Ronald Witteles, Matthew Wheeler, Patricia Ulloa, Marie Lugtu, Sally Arai, Stanley Schrier, Richard Lafayette, Michaela Liedtke; Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. Blood 2016; 128 (22): 4525.
- 戈程, 李佳月, 刘博罕, 等. 心肌淀粉样变性临床特点及远期预后的影响因素[J]. 中华老年多器官疾病杂志, 2020, 19(6):405-409.
- Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206. Epub 2016 Feb 25.
- 中国系统性轻链型淀粉样变性协作组, 国家肾脏疾病临床医学研究中心, 国家血液系统疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南(2021年修订) [J] . 中华医学杂志, 2021, 101(22) : 1646-1656.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- XDd-LCA-Phase2
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。